FOTEMUSTINE IN PATIENTS WITH RELAPSING MALIGNANT GLIOMAS - A PHASE-II TRIAL
- Authors:
- Published online on: March 1, 1995 https://doi.org/10.3892/or.2.2.307
- Pages: 307-308
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Abstract
Eleven patients with relapsing malignant glioma were treated with fotemustine chemotherapy, a new nitrosourea derivative. One partial response of 13 months duration occurred, resulting in a marked improvement of the quality of life of the patient. Seven patients had stable disease for a median duration of 5 months. Median survival from inclusion in the study was 6 months. Toxicity was mainly hematologic and manageable. We confirm that fotemustine has some activity in patients with relapsing malignant glioma.
